GlaxoSmithKline Pakistan Limited (KASE: GLAXO)
Health Care · Pharmaceuticals · PK
PKRs345.96
+1.59% today · -18.4% 1Y
GlaxoSmithKline Pakistan Limited (KASE: GLAXO) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $397.21M.
Over the last twelve months the share price has lost 18.4%, trading between 293.09 and 459.94.
Tweenvest scores GlaxoSmithKline Pakistan Limited across four factors: quality 73/100, value 69/100, growth 78/100, dividend 86/100. Its strongest factor is dividend.
GLAXO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $397.21M
- Revenue (TTM)
- $241.41M
- P/E
- 10.48
- EPS
- 33.00
- Dividend yield
- 4.99%
- Beta (5Y)
- 0.42
- 52-week high
- PKRs459.94
- 52-week low
- PKRs293.09
- Avg volume (3M)
- —
- Shares outstanding
- 318.47M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.22 | -0.96% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.15 | +0.29% |
Figures last refreshed Aug 18, 2026.